Fibrinogen

Fibrinogen, also known as coagulation factor I, is a soluble plasma glycoprotein that plays a central role in the final stages of blood clot formation. During coagulation, thrombin converts fibrinogen into fibrin, which forms a mesh that stabilizes the platelet plug and provides structural strength to the developing blood clot. Fibrinogen replacement therapy uses human fibrinogen concentrate to temporarily restore low or absent fibrinogen levels in patients with bleeding disorders. Congenital fibrinogen disorders include afibrinogenemia, in which fibrinogen is essentially absent, hypofibrinogenemia, in which levels are reduced, and dysfibrinogenemia, in which the protein is present but functionally abnormal. Fibrinogen concentrates are administered intravenously and are used according to the underlying condition, bleeding severity, laboratory results, and clinical circumstances. They may be used for acute bleeding and, depending on the specific product and regulatory approval, for prevention or management of bleeding associated with congenital deficiency and for fibrinogen supplementation in acquired deficiency. Fibrinogen is clinically important because adequate plasma fibrinogen is required for formation of a stable fibrin clot. Replacement can therefore help restore hemostasis when endogenous fibrinogen is insufficient.

Fibrinogen has long been recognized as an essential component of the coagulation system and was historically administered as plasma-derived fibrinogen preparations. Modern human fibrinogen concentrates are purified from human plasma and undergo manufacturing and pathogen-reduction processes designed to improve safety and consistency. In the United States, the FDA approved RiaSTAP, a fibrinogen concentrate containing human fibrinogen, on January 16, 2009 for treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. The FDA subsequently approved additional human fibrinogen products, including Fibryga in 2017, with its labeling later expanded to include fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency. In Europe, human fibrinogen products have been used for decades, and the European Medicines Agency established guidance covering treatment and prophylaxis of bleeding in congenital fibrinogen disorders and supplementation in acquired hypofibrinogenemia. Clinical evidence has primarily involved pharmacokinetic studies, prospective and retrospective treatment studies, perioperative experience, and clinical evaluations of fibrinogen replacement in congenital and acquired deficiency.

Human fibrinogen replacement is used primarily when fibrinogen levels are sufficiently low to impair effective clot formation and the patient is bleeding or is at significant risk of bleeding. Approved indications depend on the specific fibrinogen concentrate and jurisdiction. In the United States, RiaSTAP is indicated for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia, while Fibryga is also indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency. In clinical practice and according to applicable regulatory guidance, human fibrinogen may also be used for treatment or prophylaxis of bleeding in selected congenital fibrinogen disorders. Therapy is generally replacement treatment rather than combination therapy, although it may be administered alongside other blood components or hemostatic treatments when clinically appropriate. Human fibrinogen products are not interchangeable for every indication, and the approved indication of the specific product should be confirmed before treatment.

Fibrinogen concentrate is administered by intravenous injection or infusion after reconstitution according to the individual product instructions. Dosing is individualized according to the patient's measured or estimated fibrinogen concentration, body weight, severity and location of bleeding, and the target fibrinogen level required for adequate hemostasis. For RiaSTAP, when the baseline fibrinogen level is known, the dose is calculated using the difference between the desired target and measured fibrinogen concentration together with body weight; when the baseline level is unknown, the current prescribing information recommends an initial dose of 70 mg/kg. Fibrinogen levels should be monitored during treatment and additional dosing may be required depending on the clinical response and laboratory results. Treatment duration is determined by the underlying disorder, bleeding episode, surgical procedure, and restoration of adequate hemostasis. Product-specific dosing recommendations should always be followed.

Common or reported adverse effects of human fibrinogen concentrates may include fever, headache, nausea, chills, fatigue, and infusion-related or hypersensitivity reactions. Some patients may experience local or generalized reactions associated with administration. Because fibrinogen is derived from human plasma in many approved concentrates, manufacturing controls are used to reduce the risk of transmission of infectious agents, although this risk cannot be considered completely eliminated. The frequency and severity of adverse effects vary between products and patient populations. Most patients require clinical and laboratory monitoring so that treatment can be adjusted according to bleeding control and fibrinogen levels.

Important serious risks include thrombotic complications and severe hypersensitivity or anaphylactic reactions. Excessive fibrinogen replacement may increase the risk of thrombosis, particularly in patients with additional thrombotic risk factors or persistently elevated fibrinogen levels. Patients should therefore be monitored appropriately and dosing should be based on clinical circumstances and fibrinogen measurements when available. Human plasma-derived products also carry a theoretical risk of transmission of infectious agents despite donor screening and validated manufacturing processes. Fibrinogen concentrates are contraindicated in patients with a history of severe systemic or anaphylactic reactions to the relevant product or its components. Treatment should be interrupted or discontinued when clinically significant hypersensitivity occurs, and appropriate emergency management should be provided when required.

Before treatment, clinicians should assess the patient's bleeding history, underlying fibrinogen disorder, current fibrinogen concentration, thrombotic risk, and relevant coagulation parameters. Fibrinogen levels should be monitored during replacement therapy, particularly when repeated doses are required, because excessive replacement may increase thrombotic risk. Patients with a history of thrombosis or cardiovascular risk factors require appropriate clinical consideration. Hypersensitivity should be monitored during administration, especially in patients with previous exposure to plasma-derived products. Because human fibrinogen is a replacement coagulation factor rather than an immunosuppressive medicine, vaccine-related precautions are generally not a central concern. Classic metabolic drug interactions are not expected to be a major issue, although clinicians should review concurrent hemostatic therapies and other coagulation products because combined treatment may influence thrombotic risk. Pregnancy and pediatric use should be managed according to the specific product information and clinical circumstances.

Prescribers and pharmacists should confirm the exact fibrinogen product, indication, baseline fibrinogen concentration, patient weight, and desired treatment target before administration. Treatment should be guided by both clinical assessment of bleeding and laboratory measurement of fibrinogen when available. The reconstituted product should be prepared and administered according to the manufacturer's instructions, using appropriate aseptic technique and avoiding incompatibilities with other intravenous medicines. Patients should be observed for hypersensitivity reactions during administration and monitored for evidence of thrombosis when clinically appropriate. In congenital fibrinogen deficiency, patients with recurrent bleeding may require individualized replacement strategies under specialist hematology supervision. For major surgery or severe acquired hypofibrinogenemia, coordination with transfusion medicine, anesthesia, surgery, and hematology teams may be necessary. Pharmacists should also verify storage, reconstitution, administration rate, product-specific dosing, and compatibility requirements before dispensing or preparing therapy.